Dr. Stone Discusses Monitoring MRD in AML

(1:34)

Dr. Konopleva on the Controversies Surrounding MRD in AML

(4:53)

The role of MRD in AML regulatory decision making

(3:27)

MRD in myeloma: the FDA perspective

(1:26)

The emerging role of MRD in colorectal cancer decision making

(2:53)

Current role of MRD in AML

(1:12)

Approaches to and the use of MRD in ALL

(5:17)

Disussion on the FASCINATE \u0026 PATINA Trials in Breast Cancer straight from SABCS24

(13:2)

ClonoSEQ: evaluating MRD in CLL

(2:54)

Approaching MRD in Multiple Myeloma

(23:32)

Developments for the use of MRD in AML

(1:17)

The real world utilization of MRD in myeloma across Europe

(1:27)

The current role of MRD in AML and challenges with implementing this in clinical practice

(1:26)

The prognostic value of MRD in multiple myeloma \u0026 MRD-guided therapy

(4:16)

The role of MRD in AML

(4:22)

The importance of MRD in AML prognosis and therapy

(2:16)

Minimal residual disease (MRD) in CLL: Is it clinically relevant?

(21:9)

Measurable Residual Disease in Acute Myeloid Leukemia MRD in AML

(34:52)

MRD in AML: prognoses, transplant and treatment planning

(2:57)